Utility of No-Charge Panel Genetic Testing for Inherited Retinal Diseases in a Real-World Clinical Setting.
Utility of No-Charge Panel Genetic Testing for Inherited Retinal Diseases in a Real-World Clinical Setting.
复制标题
DOI：
10.1177/24741264221100936
复制
发表时间：
2022-09
期刊：
影响因子：
--
通讯作者：
Lee, Sun Young
中科院分区：
文献类型：
--
作者：
McClard, Cynthia K.;Pollalis, Dimitrios;Jamshidi, Farzad;Kingsley, Ronald;Lee, Sun Young
To show the utility of genetic testing in inherited retinal disease (IRD) patients. This retrospective cohort study was performed at a single academic center and comprised 59 patients clinically diagnosed with IRD who had testing via the Invitae IRD Panel (Invitae Corp). Samples were collected from August 2019 to April 2021. The rates of genetic diagnosis and disease-category specific results (ie, positive, undetermined, negative) were assessed. Testing results were returned a mean of 20 days (range, 14–28 days) after submission. Of the samples, 50.8% (30/59) had a diagnostic yield. By disease category, the yield was 46.4% (13/28) nonsyndromic retinitis pigmentosa (RP), 50.0% (4/8) syndromic RP, 46.2% (6/13) macular dystrophies, 75.0% (3/4) cone or cone-rod dystrophies, and 80.0% (4/5) other retinopathies; there were no cases of rod dystrophies. The results were undetermined in 47.5% of patients (28/59) because of identification of only 1 recessive mutation (5.1%; 3/59), 1 recessive mutation and at least 1 variant of uncertain significance (VUS) (13.6%; 8/59), or VUS only (28.8%; 17/59). One patient (1.7%) received negative testing results with no mutations or VUS identified. Open-access, no-charge panel testing offers a reasonable diagnostic yield. Accurate clinical diagnosis of IRD before testing and acknowledgment of the limitations of panel testing are critical. The results add to the current estimates of the value of genetic testing for retina specialists in the management of IRD.
登录
查看更多内容
影响因子：
8.1
作者：
Zhao, Peter Y.;Branham, Kari;Jayasundera, K. Thiran
通讯作者：
Jayasundera, K. Thiran
对1000个遗传性视网膜疾病的连续家庭进行临床焦点分子研究。
影响因子：
13.7
作者：
Stone EM;Andorf JL;Whitmore SS;DeLuca AP;Giacalone JC;Streb LM;Braun TA;Mullins RF;Scheetz TE;Sheffield VC;Tucker BA
通讯作者：
Tucker BA
影响因子：
13.7
作者：
Patel, Aara;Hayward, Jane D.;Sowden, Jane C.
通讯作者：
Sowden, Jane C.
影响因子：
13.7
作者：
Maguire, Albert M.;Russell, Stephen;Bennett, Jean
通讯作者：
Bennett, Jean
DOI：
10.1038/gim.2014.172
发表时间：
2015-04
期刊：
Genetics in medicine : official journal of the American College of Medical Genetics
影响因子：
--
作者：
Consugar MB;Navarro-Gomez D;Place EM;Bujakowska KM;Sousa ME;Fonseca-Kelly ZD;Taub DG;Janessian M;Wang DY;Au ED;Sims KB;Sweetser DA;Fulton AB;Liu Q;Wiggs JL;Gai X;Pierce EA
通讯作者：
Pierce EA